35
Retrospective Observational Study to Evaluate Long-Term Effectiveness and Safety of Omalizumab Treatment in Real-Life Setting in Allergy Centre of Spain
Saturday, March 5, 2016
South Exhibit Hall H (Convention Center)
Dorkas Margarita Marquez Hernandez, Jose A Bastidas, Lys Herraez, Elena Mederos, A. Enriquez Matas, MD, Ruth Mielgo Ballesteros, MD, Consuelo Fernandez
Rationale:

Few studies have evaluated long-term and progressive beneficial effects of omalizumab uninterrupted treatment for > 5 years in real-life practice.

The aim of this study was to evaluate the clinical and functional improvement of patients with persistent severe asthma treated with omalizumab for 5 years.

Methods:

A retrospective, observational study based on medical record reviews of patients treated with omalizumab for minimum 5 years was addressed. Annual asthma exacerbations (AE), emergency visits (EV), hospital admissions (HA), systemic corticosteroid bursts (SCOb), inhaled corticosteroids daily dose (ICS/d) and lung function (FEV1% predicted) were collected during the pre-treatment year and compared after 1 and 5 years of uninterrupted therapy. Adverse reactions (AR) were also reviewed.

Results:

14 patients were evaluated. The average age was 41.64, nine patients were female and 13 had allergic asthma. Mean values before omalizumab treatment were total IgE 767.37 KU/L, FEV1 77%, ICS/d 1000 mcg (Fluticasone), SCOb 5.5, AE 7.14, EV 3.57 and HA 0.86. AER, ERV, SCOb reduced by 65%, 80%, 73%, respectively at year 1 and 92%, 96%, 83%, respectively at year 5 of treatment. Mean FEV1 increased up 87% at year 1 and up 105 % at year 5. Pre-treatment ICS/d dose reduced by 28 % at year five and only one patient suffered 1HA at year five. Only 2 patients experienced mild headache and no serious AR were documented.

Conclusions:

Omalizumab showed an excellent tolerability and a progressive long-term effectiveness over 5 years in real-life practice, although the most improvements were experimented within the first year of treatment.